---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Axicabtagene Ciloleucel - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/axicabtageneciloleucel
version: v1
---

# Axicabtagene Ciloleucel - NCI

# Axicabtagene Ciloleucel

Placeholder slot

(AK-see-KAB-tuh-jeen sy-loh-LOO-sel)

This page contains brief information about axicabtagene ciloleucel
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Yescarta

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b70606e-b99c-4272-a0f1-b5523cce0c59&audience=consumer)

## Use in Cancer

Axicabtagene ciloleucel
is approved to treat adults with:

- **[B-cell non-Hodgkin lymphoma](/Common/PopUps/popDefinition.aspx?id=444967&version=Patient&language=English)** (NHL), including the following types:
- [diffuse large B-cell lymphoma](/Common/PopUps/popDefinition.aspx?id=428286&version=Patient&language=English) (DLBCL)
- DLBCL in patients who had [follicular lymphoma](/Common/PopUps/popDefinition.aspx?id=428287&version=Patient&language=English)
- follicular lymphoma¹
- [primary mediastinal large B-cell lymphoma](/Common/PopUps/popDefinition.aspx?id=777025&version=Patient&language=English)
- [high-grade](/Common/PopUps/popDefinition.aspx?id=45710&version=Patient&language=English) B-cell lymphoma

It is used in adults whose cancer came back or did not get better after at least two other [systemic therapies](/Common/PopUps/popDefinition.aspx?id=45922&version=Patient&language=English).
- **DLBCL** that did not respond to [first-line](/Common/PopUps/popDefinition.aspx?id=346494&version=Patient&language=English) [chemoimmunotherapy](/Common/PopUps/popDefinition.aspx?id=270867&version=Patient&language=English) or that relapsed within 12 months of first-line chemoimmunotherapy

Axicabtagene ciloleucel is only available as part of a special program called Yescarta REMS ([Risk Evaluation and Mitigation Strategies](https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=375)).

¹This use is approved under FDA’s [Accelerated Approval Program](https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm). As a condition of approval, [confirmatory trial(s)](/Common/PopUps/popDefinition.aspx?id=799146&version=Patient&language=English) must show that axicabtagene ciloleucel provides a clinical benefit in these patients.

Axicabtagene ciloleucel
is also being studied in the treatment of other types of
cancer.

## More About Axicabtagene Ciloleucel

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/768723) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Axicabtagene Ciloleucel](https://medlineplus.gov/druginfo/meds/a618003.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Understanding the Risk of Second Cancers After CAR T-Cell Therapy](https://www.cancer.gov/news-events/cancer-currents-blog/2024/car-t-cell-therapy-second-cancers)

[Trial Confirms CAR T-Cell Therapy Benefits People with Aggressive Lymphomas](https://www.cancer.gov/news-events/cancer-currents-blog/2023/large-b-cell-lymphoma-axi-cel-zuma-7-trial)

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[T-cell Transfer Therapy](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy)

[CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers](https://www.cancer.gov/about-cancer/treatment/research/car-t-cells)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Axicabtagene Ciloleucel](https://www.cancer.gov/research/participate/clinical-trials/intervention/C120309) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
